| scholarly article | Q13442814 |
| P2093 | author name string | A Walker | |
| E D Kharasch | |||
| D Whittington | |||
| C Hoffer | |||
| P S Bedynek | |||
| P2860 | cites work | Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir | Q46972814 |
| In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation | Q48473453 | ||
| Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. | Q51088676 | ||
| Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. | Q51441513 | ||
| Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine | Q61989765 | ||
| The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects | Q70399244 | ||
| St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 | Q73443725 | ||
| Alprazolam-ritonavir interaction: implications for product labeling | Q73761350 | ||
| Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents | Q77542483 | ||
| Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects | Q79448424 | ||
| Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides | Q28237138 | ||
| Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam | Q28305304 | ||
| Decreased methadone effect after ritonavir initiation | Q28368991 | ||
| OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine | Q28369686 | ||
| The effect of rifampin administration on the disposition of fexofenadine | Q32156844 | ||
| Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone | Q34348923 | ||
| Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein | Q35827580 | ||
| The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique | Q35846680 | ||
| Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents | Q36304438 | ||
| Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice | Q36465406 | ||
| An update and review of antiretroviral therapy | Q36545072 | ||
| Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance | Q36641884 | ||
| Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans | Q40398090 | ||
| Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine | Q40753067 | ||
| Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line | Q40763015 | ||
| Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers | Q42630554 | ||
| Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1) | Q42758868 | ||
| Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir | Q43760231 | ||
| Effect of St John's wort on the pharmacokinetics of fexofenadine | Q44043537 | ||
| Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir | Q44202487 | ||
| Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration | Q44217895 | ||
| Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein | Q44312369 | ||
| Variable modulation of opioid brain uptake by P-glycoprotein in mice | Q44344008 | ||
| Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects | Q44346900 | ||
| The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients | Q44540993 | ||
| Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine | Q44637319 | ||
| Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human | Q44650608 | ||
| Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice | Q44719752 | ||
| Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats | Q44777237 | ||
| Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes | Q44913929 | ||
| Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis | Q45146008 | ||
| Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes | Q45158721 | ||
| Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination | Q45188831 | ||
| Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics | Q45215056 | ||
| Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. | Q45282861 | ||
| Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions | Q45401784 | ||
| CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition | Q46580820 | ||
| Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism | Q46638501 | ||
| Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. | Q46964154 | ||
| The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates | Q46972809 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| ritonavir | Q422618 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 506-512 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities | |
| P478 | volume | 84 |
| Q34573885 | Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates |
| Q50668713 | Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. |
| Q30234940 | Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions. |
| Q43254867 | Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients |
| Q35776626 | Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion |
| Q36646017 | Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil |
| Q50682107 | Current Concepts in Methadone Metabolism and Transport. |
| Q36036200 | Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics |
| Q37325606 | Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir |
| Q54646435 | Drug interactions with methadone: Time to revise the product label. |
| Q36326853 | Effect of HAART on Brain Organization and Function in HIV-Negative Subjects |
| Q35000765 | Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals |
| Q46780885 | Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro |
| Q37705351 | Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation |
| Q47303894 | Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. |
| Q37113947 | Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. |
| Q42931493 | Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase |
| Q39245872 | Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings |
| Q36652680 | Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). |
| Q59357868 | Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women |
| Q26775832 | Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy |
| Q36693543 | Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics |
| Q36641884 | Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance |
| Q48092928 | Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs |
| Q38880731 | Membrane Assays to Characterize Interaction of Drugs with ABCB1. |
| Q36637864 | Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity |
| Q34604652 | Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir |
| Q35087543 | Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment |
| Q42941908 | Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir |
| Q36578070 | Perioperative pharmacokinetics of methadone in adolescents |
| Q46003084 | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? |
| Q36072448 | Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies |
| Q33806539 | S-Methadone augments R-methadone induced respiratory depression in the neonatal guinea pig. |
| Q38478413 | Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions |
Search more.